The European Medicines Agency has listed Guillain-Barre syndrome (GBS), a neurological disorder known to cause temporary paralysis, as a very rare side effect of AstraZeneca COVID-19 vaccine.

With 833 cases of GBS reported worldwide as of July 31, from around 592 million doses of the AstraZeneca "Vaxzevria" vaccine administered, the EMA stated that a causal relationship was "considered at least a reasonable possibility".

The EMA said that GBS should be added to the product information as a side effect of the vaccine, and stated that the syndrome was a very rare side effect, noted in less than one in 10,000 individuals… (NDTV – AFP, September 9, 2021)